Q4 Results 05th May Live: L&T, M&M, Hero MotoCorp, Coforge, SRF, United Breweries, Lloyds Metals & Energy, Marico, Emcure Pharma, PNB, Poonawalla to announce Q4 results, Ambuja Cements, BHEL, Tata Tech, Aditya Birla Capital, Godrej Prop, CAMS, Exide, Ather & Quess Corp shares in focus
2 min readACUTAAS CHEMICALS – CONCALL HIGHLIGHTS
Battery Chemicals Expansion
– Phase‑1 capital expenditure completed at Jhagadia
– 2,000 MT capacity for VC and FEC established
– Secured three‑year supply contracts
– Production has started
– Revenue expected to ramp up through FY27
– Phase‑2 capex scheduled for Q1FY27
– Work on third‑product capex underway
– Two additional products slated for launch in FY27
CDMO Pipeline
– Four products have completed commercial validation
– Currently undergoing regulatory approval
– Each could generate peak revenues of ₹50‑100 Cr
– Anticipated ramp‑up by FY28
– A ten‑year supply agreement is in place
– Strong relationships with global clients
Growth Outlook
– FY27 revenue projected to grow about 25%
– Consistent performance over the past decade
– Three primary growth drivers powering the business
– Pharma CDMO remains the largest contributor
– Battery chemicals business is scaling up
– Semiconductor segment showing signs of recovery
Margins & Capex
– EBITDA margin expected around 34.5‑35%
– FY27 capex planned at roughly ₹90 Cr
– Includes carry‑over and maintenance spends
– R&D expansion under review
R&D Expansion
– Ten‑fold increase in R&D capacity envisaged
– Multi‑sector R&D capabilities being built
– Focus on pharma, battery and semiconductor areas
– Aiming to sustain a long‑term innovation pipeline
Management Commentary
– Battery and semiconductor segments set to become key growth engines
– Independent growth anticipated by FY28
– CDMO ramp‑up expected to accelerate post‑commercialization
– Visibility of sustained growth
Final Takeaway
– Robust multi‑engine growth model in place
– Focus on high‑margin specialty chemicals
– Successful execution will be critical for the next phase
Disclaimer
– This is not a buy or sell recommendation
About Author
